HTEC Index 2nd QTR 2026 Commentary

As of June 30, 2026

The ROBO Global Healthcare Technology and Innovation Index (HTEC) ended the second quarter with a return of 14.08%. Following a turbulent start to the year characterized by broader market risk-off rotations and geopolitical tensions, Q2 saw a steady recovery across the healthcare technology space.

This rebound was driven in good part by solid earnings execution and a strong performance in the Genomics subsector. Eight of the index's nine subsectors generated positive returns during the period. This broad participation underscores a stabilizing macro environment where investors are again rewarding fundamental operational strength.

Genomics led the index with a **60.94%** return. As AI makes developing drug candidates faster and cheaper, demand keeps increasing for the underlying technologies that bring these treatments into the real world. Other top contributing subsectors included **Data Analytics** at **17.73%** and **Process Automation** at **12.54%**.

Within the Genomics subsector, **Twist Bioscience Corp** was a top performer, returning **116.50%**. The company benefited from reporting strong sequential revenue growth and securing a new financing facility that alleviated lingering balance sheet concerns.

Veracyte Inc also contributed heavily to the growth of the subsegment, posting an **82.33%** gain. Its advanced diagnostic tests achieved broader commercial payer coverage and scale during the quarter.

The broader **Medical Instruments** subsector grew **9.85%**. **Integra LifeSciences Holdings Corp** was a notable driver here, returning **90.66%**. This increase followed a first-quarter earnings report that highlighted improved operating margins and successful manufacturing optimization efforts, which met analyst expectations.

In the **Data Analytics** space, **Tempus AI Inc** advanced **28.11%**. The company successfully capitalized on sustained demand for real-world clinical data integration.

Telehealth was the only subsector to post a negative return, declining **20.08%**. The group faced continued operational headwinds in international markets as consumer behavior shifted back toward traditional in-person care models. This shift caused multiple compressions across digital platforms.

Within **Telehealth**, **Alibaba Health Information Technology Ltd** fell **33.92%**. **JD Health International Inc** also experienced a significant drop, falling **30.23%**.

In the Medical Instruments group, **Boston Scientific Corporation** dropped **31.98%**. This decline occurred after the company adjusted its organic revenue forecast, which prompted a selloff despite the firm maintaining a highly profitable core business.

In the **Regenerative Medicine** subsector, **Artivion Inc** fell **38.64%**. This selloff followed a reduction in its full-year revenue guidance that offset positive market sentiment from recent regulatory product approvals.

The fundamental drivers for healthcare technology remain firmly intact. Core industry challenges such as aging populations, clinical labor shortages, and rising healthcare costs are only accelerating. These factors create a sustained demand curve for efficiency-enhancing technologies.

While multiple sensitivities persist for large-cap medical devices, the underlying durability of these businesses is steady. Companies within the HTEC index remain well positioned to capture long-term value by delivering the specific clinical and technological solutions needed to solve these systemic problems. The focus moving forward will likely remain on execution, cash flow generation, and the successful commercial scaling of next-generation platforms.

About VettaFi

VettaFi is a provider of indexing, data & analytics, industry leading conferences, and digital distribution services to ETF issuers and fund managers. It operates the ETFdb and Advisor Perspectives websites, and the LOGICLY portfolio analytics platform—engaging millions of investors annually— empowering and educating the modern financial advisor and institutional investor. VettaFi owns and administers the ROBO Global Index Series. For more information, please visit: www.vettafi.com.

VettaFi LLC, is a wholly owned subsidiary of TMX Group Limited (TMX Group). For more information about TMX Group, please visit: www.tmx.com.

vettafi.com | 225 Liberty Street, 23rd Floor, New York, NY 10281

VettaFi Disclaimer

This Document Is Impersonal and Not a Solicitation. ROBO Global, LLC is a wholly owned subsidiary of VettaFi LLC. VettaFi LLC, collectively with its affiliates and subsidiaries, is referred to herein as (“VettaFi”). This document does not constitute an offering of any security, product, or service. All information provided by VettaFi in this document is impersonal and not customized to the specific needs of any entity, person, or group of persons.

About the Index. The ROBO Global® Healthcare Technology and Innovation Index Series' objective is to provide investors with comprehensive, transparent and diversified benchmarks representing the global value chain of disruptive and emerging technologies in the healthcare sector. The index series benchmark companies that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. The Index and its trademarked name are the exclusive property of VettaFi.

No Advisory Relationship. VettaFi is not a fiduciary or an investment advisor, and VettaFi makes no representation regarding the advisability of investing in any investment fund or other vehicle. This document should not be construed to provide advice of any kind, including, but not limited to, investment, tax or legal.

You Must Make Your Own Investment Decision. It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. You should not make a decision to invest in any investment fund or other vehicle based on the statements set forth in this document. You should only make an investment in an investment fund or other vehicle after carefully evaluating the risks associated with such an investment in the investment fund, as detailed in the offering memorandum or similar document prepared by or on behalf of the issuer. This document does not contain, and does not purport to contain, the level of detail necessary to give sufficient basis to an investment decision. VettaFi does not sponsor, endorse, sell, promote, or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index.

No Warranties; Limitation of Liability. While VettaFi believes that the information contained in this document (collectively, the “Content”) is reliable, VettaFi does not guarantee the accuracy, completeness, timeliness, or availability of the Content in whole or in part. VettaFi is not responsible for any errors or omissions, regardless of the cause, in the Content which may change without notice. VettaFi makes no warranties, express or implied, as to results to be obtained from use of the Content, and VettaFi expressly disclaims all warranties of suitability with respect thereto. VettaFi shall not be liable for any claims or losses of any nature in connection with the use of the Content, including but not limited to, lost profits or punitive or consequential damages, even if VettaFi has been advised of the possibility of same.

Research May Not Be Current. This document has been prepared solely for informational purposes based on information generally available to the public from sources believed to be reliable. VettaFi does not assume any obligation to update the Content following publication in any form or format.